Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins

Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins

Show other versions (2)

Bibliographic Details
Main Authors:	Reilly, S, Jayaram, R, Nahar, K, Antoniades, C, Verheule, S, Channon, K, Alp, N, Schotten, U, Casadei, B
Format:	Journal article
Published:	2011

Similar Items

Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins.
by: Reilly, S, et al.
Published: (2011)

Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins.
by: Reilly, SN, et al.
Published: (2011)

ATRIAL SOURCES OF REACTIVE OXYGEN SPECIES VARY WITH THE SUBSTRATE AND DURATION OF ATRIAL FIBRILLATION: IMPLICATIONS FOR THE ANTIARRHYTHMIC EFFECT OF STATINS
by: Reilly, S, et al.
Published: (2011)

Molecular Basis of Atrial Nitroso-Redox Imbalance in Permanent Human Atrial Fibrillation
by: Reilly, S, et al.
Published: (2009)

Atrial Fibrillation Causes a Progressive, Time-Dependent Reduction in Myocardial Neuronal NOS in Humans and Goats: Implications for AF-Induced Electrical Remodeling
by: Reilly, S, et al.
Published: (2012)

Considerations for the Assessment of Substrates, Genetics and Risk Factors in Patients with Atrial Fibrillation
by: Dominik Linz, et al.
Published: (2021-10-01)

Emerging Antiarrhythmic Drugs for Atrial Fibrillation
by: Arnela Saljic, et al.
Published: (2022-04-01)

Time-Dependent and Regional Differences in Myocardial Nitric Oxide-Redox State in Atrial Fibrillation
by: Reilly, S, et al.
Published: (2008)

Time-dependent regional differences in sources of oxidative stress in atrial fibrillation-induced remodelling
by: Reilly, SN, et al.
Published: (2008)

Molecular mechanisms underlying the myocardial nitric oxide-redox imbalance in human atrial fibrillation
by: Reilly, SN, et al.
Published: (2009)

ANTIARRHYTHMIC EFFICACY OF PROPAFENONE IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION
by: R. D. Kurbanov, et al.
Published: (2016-01-01)

ANTIARRHYTHMIC EFFICACY OF PROPAFENONE IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION
by: R. D. Kurbanov, et al.
Published: (2016-01-01)

Myocardial Redox State Predicts Post-Operative Atrial Fibrillation in Cardiac Surgery
by: Demosthenous, M, et al.
Published: (2011)

Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging
by: Gheorghe-Andrei Dan, et al.
Published: (2018-12-01)

Myocardial superoxide and peroxynitrite as strong independent predictors of paroxysmal atrial fibrillation post-CABG
by: Demosthenous, M, et al.
Published: (2011)

Is increased myocardial oxidative stress an early event in the natural history of atrial fibrillation?
by: Reilly, S, et al.
Published: (2007)

Rearrangement of Atrial Bundle Architecture and Consequent Changes in Anisotropy of Conduction Constitute the 3-Dimensional Substrate for Atrial Fibrillation
by: Maesen, B, et al.
Published: (2013)

Rearrangement of atrial bundle architecture and consequent changes in anisotropy of conduction constitute the 3-dimensional substrate for atrial fibrillation.
by: Maesen, B, et al.
Published: (2013)

Antiarrhythmic therapy in the treatment of atrial fibrillation: yesterday, today, tomorrow
by: V. I. Podzolkov, et al.
Published: (2019-06-01)

Computational Modeling for Antiarrhythmic Drugs for Atrial Fibrillation According to Genotype
by: Inseok Hwang, et al.
Published: (2021-05-01)

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
by: Jordi Heijman, et al.
Published: (2013-08-01)

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
by: Jordi Heijman, et al.
Published: (2013-01-01)

Current strategies of antiarrhythmic drug therapy for paroxysmal atrial fibrillation
by: Takashi Komatsu
Published: (2012-06-01)

Options for antiarrhythmic therapy after surgical treatment of the atrial fibrillation
by: V. V Bazylev, et al.
Published: (2015-12-01)

Different sources of oxidant stress in the early and late stage of atrial fibrillation
by: Reilly, SN, et al.
Published: (2008)

Evaluation of the role of miR-31-dependent reduction in dystrophin and nNOS on atrial-fibrillation-induced electrical remodelling in man
by: Reilly, S, et al.
Published: (2015)

Corrigendum: Computational modeling for antiarrhythmic drugs for atrial fibrillation according to genotype
by: Inseok Hwang, et al.
Published: (2022-12-01)

The Resurfacing of Bepridil Hydrochloride on the World Stage as an Antiarrhythmic Drug for Atrial Fibrillation
by: Yuji Nakazato, MD, PhD
Published: (2009-01-01)

Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation
by: Wang A
Published: (2012-06-01)

Statins in Secondary Prevention of Atrial Fibrillation
by: V. I. Podzolkov, et al.
Published: (2016-11-01)

ADJUSTMENT OF PHARMACOLOGICAL ANTIARRHYTHMIC THERAPY IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION DURING SERIAL TESTING OF ANTIARRHYTHMIC DRUGS WITH TRANSESOPHAGEAL ELECTROPHYSIOLOGICAL STUDIES
by: K. A. Skiba, et al.
Published: (2003-06-01)

ORAL INTAKE OF LOADING DOSES OF ANTIARRHYTHMIC DRUGS FOR SINUS RHYTHM RESTORATION IN ATRIAL FIBRILLATION
by: E. O. Khamitsayeva, et al.
Published: (2003-06-01)

CHANGES IN THE LEVEL OF NATRIURETIC PEPTIDES IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ANTIARRHYTHMIC DRUGS
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Racial and Ethnic Differences in Initiation and Discontinuation of Antiarrhythmic Medications in Management of Atrial Fibrillation
by: Kipp R, et al.
Published: (2024-03-01)

CHANGES IN THE LEVEL OF NATRIURETIC PEPTIDES IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ANTIARRHYTHMIC DRUGS
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Antiarrhythmic therapy choice in patients with left ventricular diastolic dysfunction and atrial fibrillation
by: A. V. Tarasov, et al.
Published: (1970-01-01)

Undiagnosed sleep apnea in patients with atrial fibrillation: An underutilized opportunity for antiarrhythmic management
by: Maartje J.M. Hereijgers, et al.
Published: (2022-06-01)

Effects of peri-operative statin treatment on atrial electrical properties, post-operative atrial fibrillation and in-hospital clinical outcomes in patients undergoing elective cardiac surgery
by: Jayaram, R
Published: (2014)

Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter
by: E B Maĭkov, et al.
Published: (2015-01-01)

Nationwide survey of catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF) – Report on antiarrhythmic drug therapy
by: Yuji Murakawa, MD, et al.
Published: (2014-10-01)